Iain Stuart

Iain Stuart

Company: Foamix Pharmaceuticals

Job title: Chief Scientific Officer

Bio:

Iain A. Stuart, PhD has served as Chief Scientific Officer of Foamix Pharmaceuticals, Inc since January 2019. Dr. Stuart joined Foamix in October 2016, and previously served as Senior Vice President of Research and Development and Vice President Clinical Development. He has over 22 years of pharmaceutical industry experience with the last 12 years focused primarily in dermatology research and development. He previously holding various positions at LEO Pharma, Inc. from 2008 to 2016, including Director of Preclinical Development, Director of Clinical Operations, Vice President of Research and Development Project Management, and, most recently, as Vice President of Medical Strategy and Scientific Affairs. Prior to LEO Pharma, Dr. Stuart served as Senior Study Director at Inveresk Research (now Charles River), and as Project Manager, Pharmaceutical Development at Cyclacel Pharmaceuticals, Inc. Dr. Stuart has a PhD and first-class honors BSc in chemistry from Glasgow Caledonian University, UK and was a postdoctoral fellow in medicinal chemistry at the University of Strathclyde, UK.

Seminars:

Panel Discussion: The Evolving Clinical, Regulatory & Commercial Paradigm in Dermatology 4:15 pm

• Assessing the need for cooperation between regulators, payers and drug developers in the definition of appropriate endpoints in the development of dermatological therapies • Supporting value-based evidence to external stakeholders: Establishing the value of new therapies and effectively demonstrating improved outcomes • Discussing the different payer requirements between Europe and US • Navigating the…Read more

day: Day Two

Case Study by Foamix Pharmaceuticals: AMZEEQTM; Topical Minocycline is Now a Reality 12:15 pm

• A deep dive into the historical development of a hydrophobic vehicle system to support dermal delivery of minocycline HCl • Assessing the roles of administration route, vehicle and antibiotic choice in the mitigation of resistance development potential • Showcasing topline data from the AMZEEQTM phase III programmeRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.